This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (127)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Joan W. Miller, MD; Arthur W. Walsh, MD; Michal Kramer, MD; Tayyaba Hasan, PhD; Norman Michaud, MS; Thomas J. Flotte, MD; Robert Haimovici, MD; Evangelos S. Gragoudas, MD

Arch Ophthalmol. 1995;113(6):810-818.

Abstract
Objective
To investigate photodynamic therapy of experimental choroidal neovascularization using benzoporphyrin derivative monoacid (Verteporfin).

Methods
Photodynamic therapy using benzoporphyrin derivative monoacid was investigated in cynomolgus monkeys. Following intravenous injection of benzoporphyrin derivative monoacid (1 to 2 mg/kg) complexed with low-density lipoprotein, the eyes were irradiated with 692-nm light at a fluence of 50 to 150 J/cm² and irradiance of 150 to 600 mW/cm². Choroidal neovascularization was documented before photodynamic therapy and closure was demonstrated by fundus photography, fluorescein angiography, and light and electron microscopic examination.

Results
Following photodynamic therapy, vessels within choroidal neovascularization were occluded, and there was damage to the choroidal neovascularization endothelium and the subjacent choriocapillaris. Damage to the retinal pigment epithelium and photoreceptors was also observed.

Conclusion
Photodynamic therapy with lipoprotein-delivered benzoporphyrin derivative monoacid was effective in this animal model of choroidal neovascularization and may be a promising, potentially selective, therapy for choroidal neovascularization.

Author Affiliations
From the Laser Research Laboratory, Retina Service, Massachusetts Eye and Ear Infirmary (Drs Miller, Walsh, Kramer, Haimovici, and Gragoudas), and the Department of Dermatology, Wellman Laboratories of Photomedicine, Massachusetts General Hospital (Drs Hasan and Flotte and Mr Michaud), Harvard Medical School, Boston. The Massachusetts Eye and Ear Infirmary has a proprietary interest in this technology under a reasearch agreement with Coherent Inc, Palo Alto, Calif, and as part of a patent application. Drs Miller and Gragoudas are participants in this agreement and application under the established guidelines of Harvard Medical School.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Photoreceptor Protection after Photodynamic Therapy Using Dexamethasone in a Rat Model of Choroidal Neovascularization
She et al.
IOVS 2008;49:5008-5014.
ABSTRACT | FULL TEXT  

A prospective randomised study on low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration
Odergren et al.
Br J Ophthalmol 2008;92:757-761.
ABSTRACT | FULL TEXT  

Correlation between Focal Macular Electroretinograms and Angiographic Findings after Photodynamic Therapy
Ishikawa et al.
IOVS 2007;48:2254-2259.
ABSTRACT | FULL TEXT  

Reduced Photoreceptor Damage after Photodynamic Therapy through Blockade of Nitric Oxide Synthase in a Model of Choroidal Neovascularization
She et al.
IOVS 2007;48:2268-2277.
ABSTRACT | FULL TEXT  

Investigating the effect of ciliary body photodynamic therapy in a glaucoma mouse model.
Matsubara et al.
IOVS 2006;47:2498-2507.
ABSTRACT | FULL TEXT  

A 76-year-old man with macular degeneration.
Arroyo
JAMA 2006;295:2394-2406.
FULL TEXT  

Anastomotic Vessels Remain Viable after Photodynamic Therapy in Primate Models of Choroidal Neovascularization
Criswell et al.
IOVS 2005;46:2168-2174.
ABSTRACT | FULL TEXT  

Selective Photodynamic Therapy by Targeted Verteporfin Delivery to Experimental Choroidal Neovascularization Mediated by a Homing Peptide to Vascular Endothelial Growth Factor Receptor-2
Renno et al.
Arch Ophthalmol 2004;122:1002-1011.
ABSTRACT | FULL TEXT  

Subthreshold Transpupillary Thermotherapy Reduces Experimental Choroidal Neovascularization in the Mouse without Collateral Damage to the Neural Retina
Ming et al.
IOVS 2004;45:1969-1974.
ABSTRACT | FULL TEXT  

The Squirrel Monkey: Characterization of a New-World Primate Model of Experimental Choroidal Neovascularization and Comparison with the Macaque
Criswell et al.
IOVS 2004;45:625-634.
ABSTRACT | FULL TEXT  

Choroidal Neovascular Membranes Treated With Photodynamic Therapy
Arroyo et al.
Arch Ophthalmol 2003;121:898-903.
FULL TEXT  

Sequence of Early Vascular Events after Photodynamic Therapy
Michels and Schmidt-Erfurth
IOVS 2003;44:2147-2154.
ABSTRACT | FULL TEXT  

Age-Related Macular Degeneration
Gottlieb
JAMA 2002;288:2233-2236.
FULL TEXT  

Verteporfin Photodynamic Therapy in the Rat Model of Choroidal Neovascularization: Angiographic and Histologic Characterization
Zacks et al.
IOVS 2002;43:2384-2391.
ABSTRACT | FULL TEXT  

Photodynamic Effects on Choroidal Neovascularization and Physiological Choroid
Schmidt-Erfurth et al.
IOVS 2002;43:830-841.
ABSTRACT | FULL TEXT  

PDT to Monkey CNV with ATX-S10(Na): Inappropriateness of Early Laser Irradiation for Selective Occlusion
Obana et al.
IOVS 2001;42:2639-2645.
ABSTRACT | FULL TEXT  

Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy
Schnurrbusch et al.
Br J Ophthalmol 2001;85:1086-1091.
ABSTRACT | FULL TEXT  

Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy
SOUBRANE and BRESSLER
Br J Ophthalmol 2001;85:483-495.
FULL TEXT  

Photodynamic Therapy Using Lu-Tex Induces Apoptosis In Vitro, and Its Effect Is Potentiated by Angiostatin in Retinal Capillary Endothelial Cells
Renno et al.
IOVS 2000;41:3963-3971.
ABSTRACT | FULL TEXT  

Selective Photodynamic Effects of the New Photosensitizer ATX-S10(Na) on Choroidal Neovascularization in Monkeys
Obana et al.
Arch Ophthalmol 2000;118:650-658.
ABSTRACT | FULL TEXT  

Photodynamic Therapy with Verteporfin (Visudyne): Impact on Ophthalmology and Visual Sciences
Bressler and Bressler
IOVS 2000;41:624-628.
FULL TEXT  

A Preliminary Study of Photodynamic Therapy Using Verteporfin for Choroidal Neovascularization in Pathologic Myopia, Ocular Histoplasmosis Syndrome, Angioid Streaks, and Idiopathic Causes
Sickenberg et al.
Arch Ophthalmol 2000;118:327-336.
ABSTRACT | FULL TEXT  

Age-Related Macular Degeneration
Fine et al.
NEJM 2000;342:483-492.
FULL TEXT  

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin: One-Year Results of 2 Randomized Clinical Trials--TAP Report 1
Treatment of Age-related Macular Degeneration With
Arch Ophthalmol 1999;117:1329-1345.
ABSTRACT | FULL TEXT  

Effects of Photodynamic Therapy Using Verteporfin on Experimental Choroidal Neovascularization and Normal Retina and Choroid up to 7 Weeks after Treatment
Husain et al.
IOVS 1999;40:2322-2331.
ABSTRACT | FULL TEXT  

Photodynamic Therapy With Verteporfin for Choroidal Neovascularization Caused by Age-related Macular Degeneration: Results of a Single Treatment in a Phase 1 and 2 Study
Miller et al.
Arch Ophthalmol 1999;117:1161-1173.
ABSTRACT | FULL TEXT  

Photodynamic Therapy With Verteporfin for Choroidal Neovascularization Caused by Age-related Macular Degeneration: Results of Retreatments in a Phase 1 and 2 Study
Schmidt-Erfurth et al.
Arch Ophthalmol 1999;117:1177-1187.
ABSTRACT | FULL TEXT  

Intravenous Infusion of Liposomal Benzoporphyrin Derivative for Photodynamic Therapy of Experimental Choroidal Neovascularization
Husain et al.
Arch Ophthalmol 1996;114:978-985.
ABSTRACT  

Photodynamic Therapy of Pigmented Choroidal Melanomas Using a Liposomal Preparation of Benzoporphyrin Derivative
Young et al.
Arch Ophthalmol 1996;114:186-192.
ABSTRACT